Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

ANVS


Fundamental

Company: Annovis Bio Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NYSE
Index: -
P/E: -
EPS (ttm): -1.48
Insider Own: 15.45%
Shs Outstand: 26.50M
Perf Week: 3.97%
Market Cap: 104.16M
Forward P/E: -
EPS next Y: -1.30
Insider Trans: 41.08%
Shs Float: 22.41M
Perf Month: 1.29%
Enterprise Value: 88.87M
PEG: -
EPS next Q: -0.31
Inst Own: 11.41%
Short Float: 12.63%
Perf Quarter: 76.23%
Income: -24.88M
P/S: -
EPS this Y: 43.52%
Inst Trans: 1.92%
Short Ratio: 1.52
Perf Half Y: 28.43%
Sales: 0.00M
P/B: 6.03
EPS next Y Percentage: 0.22%
ROA: -157.74%
Short Interest: 2.83M
Perf YTD: -21.87%
Book/sh: 0.65
P/C: 6.81
EPS next 5Y: 18.51%
ROE: -246.14%
52W High: 5.60 -29.82%
Perf Year: -16.56%
Cash/sh: 0.58
P/FCF: -
EPS past 3/5Y: -6.68% -73.95%
ROIC: -189.15%
52W Low: 1.11 254.05%
Perf 3Y: -67.68%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 9.30%
Volatility M: 11.96%
Perf 5Y: -34.46%
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: 62.84%
Oper. Margin: -
ATR (14): 0.42
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 4.60
Sales Y/Y TTM: -
Profit Margin: -
RSI (14): 53.16
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 4.60
EPS Q/Q: 62.13%
SMA20: -7.70%
Beta: 1.46
Target Price: 12.50
Payout: -
Debt/Eq: 0.00
Sales Q/Q: -
SMA50: 27.73%
Rel Volume: 0.34
Prev Close: 3.65
Employees: 8
LT Debt/Eq: 0.00
Earnings: Nov 12 BMO
SMA200: 63.26%
Avg Volume: 1.86M
Price: 3.93
IPO: Jan 29, 2020
Option/Short: Yes / Yes
EPS/Sales Surpr.: 1.78% -
Trades:
Volume: 623,867
Change: 7.67%

Technical:


Latest News:

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference neutral
ANVS AVXL LGVN

Summary: Annovis Bio Inc. will participate in the H.C. Wainwright 26th Annual Global Investment Conference with a company presentation by Dr. Maccecchini discussing recent advancements and strategic direction, followed by a panel discussion on innovative non-amyloid approaches in Alzheimer’s disease.

Full article
2024-09-05T13:33:22Z
Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences ... somewhat bullish
ANVS GILD OMGA

Summary: Analysts provide new ratings for Annovis Bio, Gilead Sciences, and Omega Therapeutics with price targets.

Full article
2024-04-30T16:25:22Z